NCI declares state of crisis in trials
An NCI report concluded that our clinical trial system is nearing a “state of crisis.” This seems like a case of new report, same conclusion.
An NCI report concluded that our clinical trial system is nearing a "state of crisis." This seems like a case of new report, same conclusion. "A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program," identified reasons for our system's lack of production including the time it takes to organize and launch a trial: More than two years of slugging through a Kafkaesque maze of bureaucracy and, if the trial finishes at all, the compound or therapy has a good chance of being out of date. Randomized controlled trials are still the gold standard for cancer agents to move from bench to bedside. We need to make it a national priority to streamline this overwrought process.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
![“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F7d7dfad7849391f4be3ebd2cf39c24f5369cfcd1-1200x1176.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).")
